Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Apr 7:2022:2004973.
doi: 10.1155/2022/2004973. eCollection 2022.

Effect of Apatinib Combined with Seggio on the Expression of Serum AFP and CA724 and Long-Term Survival Rate in Patients with Advanced Gastric Cancer Undergoing Comfortable Nursing Intervention

Dawei Ren  1 , Mi Feng  2 , Shengmin Zhang  3 , Yun Zhang  4 , Ji Li  5
Affiliations
Clinical Trial

Effect of Apatinib Combined with Seggio on the Expression of Serum AFP and CA724 and Long-Term Survival Rate in Patients with Advanced Gastric Cancer Undergoing Comfortable Nursing Intervention

Dawei Ren et al. J Healthc Eng. .

Retraction in

Abstract

Objective: To study the effect of apatinib combined with seggio on the expression of serum AFP and CA724 and the long-term survival rate in advanced gastric cancer patients undergoing comfort nursing intervention.

Methods: 98 advanced gastric cancer patients were divided into single-drug group and joint group. Both groups of patients were given comfort nursing intervention, the single-drug group was treated with seggio, and the joint group was treated with apatinib and seggio. The clinical efficacy, survival rate, relationship between the tumor markers and the survival time, serum tumor markers levels (CA724 and AFP), inflammatory factors (IL-4, IL-10) levels, quality-of-life scores, and immunity function were measured after treatment.

Results: The clinical efficacy in the joint group was better than that in the single-drug group. The three-year survival time in the joint group was upregulated relative to the single-drug group. The patients with high expression of CA724 or AFP had a lower survival time than the patients with low expression of CA724 or AFP. After treatment, IL-10 and IL-4 levels were obviously decreased, and the joint group showed a more obvious decrease compared with the single-drug group. The quality-of-life scores were significantly upregulated after treatment, and compared with the joint group, the scores in the single drug-group were obviously higher. The CD4+/CD8+, CD4+, and CD3+ levels were increased, while CD8+ levels were decreased after treatment, and the changes of each index in the joint group were more significant than those in the single-drug group. The content of CA724 and AFP were significantly decreased after treatment, and the joint group showed a more significant decrease than the single-drug group.

Conclusion: Apatinib combined with seggio for advanced gastric cancer patients' treatment based on comfort nursing intervention can improve the clinical efficacy and survival time, reduce inflammatory factors and serum tumor markers levels, enhance patients' immune function, and quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Measurement of inflammatory factors levels.  ∗P < 0.01 vs before treatment, #P < 0.01 vs joint group. (a) Detection of IL-4 levels in the two groups; (b) Detection of IL-10 levels in the two groups.
Figure 2
Figure 2
Measurement of immune function. ∗P < 0.01 vs before treatment. #P < 0.01 vs joint group. (a) Measurement of CD3+ levels in the two groups. (b) Measurement of CD4+ levels in the two groups. (c) Measurement of CD8+ levels in the two groups. (d) Measurement of CD4+/CD8+ levels in the two groups.
Figure 3
Figure 3
Measurement of tumor marker levels in the two groups. (a) Measurement of CA724 levels. (b) Measurement of AFP levels.
Figure 4
Figure 4
Measurement of three-year cumulative survival rates.
Figure 5
Figure 5
The relationship between the expression of tumor markers in the joint group and survival time. (a) The relationship between CA724 expression and survival time. (b) The relationship between AFP expression and survival time.
See this image and copyright information in PMC

References

    1. Poorolajal J., Moradi L., Mohammadi Y., Cheraghi Z., Gohari-Ensaf F. Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiology and Health . 2020;42 doi: 10.4178/epih.e2020004.e2020004 - DOI - PMC - PubMed
    1. Balakrishnan M., George R., Sharma A., Graham D. Y. Changing trends in stomach cancer throughout the World. Current Gastroenterology Reports . 2017;19(8):p. 36. doi: 10.1007/s11894-017-0575-8. - DOI - PMC - PubMed
    1. Machlowska J., Baj J., Sitarz M., Maciejewski R., Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. International Journal of Molecular Sciences . 2020;21(11):p. 4012. doi: 10.3390/ijms21114012. - DOI - PMC - PubMed
    1. Tan Z. Recent advances in the surgical treatment of advanced gastric cancer: a review. Medical Science Monitor . 2019;25:3537–3541. doi: 10.12659/msm.916475. - DOI - PMC - PubMed
    1. Song Z., Wu Y., Yang J., Yang D., Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine . 2017;39(7) doi: 10.1177/1010428317714626.1010428317714626 - DOI - PubMed

Publication types